Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Buy” from Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $27.80.

TBPH has been the subject of several research reports. BTIG Research raised their price objective on shares of Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday, November 26th. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, January 3rd. HC Wainwright boosted their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Oppenheimer initiated coverage on shares of Theravance Biopharma in a research note on Wednesday, December 3rd. They set an “outperform” rating and a $27.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th.

Theravance Biopharma Stock Down 0.5%

Shares of NASDAQ TBPH opened at $20.01 on Thursday. The stock has a market cap of $1.01 billion, a P/E ratio of 35.11 and a beta of 0.14. The firm’s 50-day simple moving average is $18.70 and its 200 day simple moving average is $15.16. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $20.79.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. Theravance Biopharma had a net margin of 36.53% and a return on equity of 12.20%. The company had revenue of $19.99 million for the quarter, compared to the consensus estimate of $19.89 million. On average, sell-side analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Activity

In related news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the sale, the senior vice president directly owned 277,695 shares in the company, valued at approximately $5,206,781.25. This trade represents a 10.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 6.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Theravance Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP acquired a new stake in shares of Theravance Biopharma during the 3rd quarter valued at $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares in the last quarter. CIBC Private Wealth Group LLC boosted its position in Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 4,662 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Theravance Biopharma in the 3rd quarter worth about $101,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.